CD274 and neoplasm: According to our results, PD-L1 status alone cannot be used as a reliable biomarker of therapeutic response to anti-PD-1 immunotherapy but could be combined with other criteria, e.g., synchronous metastases, > 10% CD163+ histocytes at advancing tumour edges or NRAS status (as previously reported19).